COVID-19 has disrupted how ophthalmic practice is conducted worldwide. One patient population that may suffer from poor outcomes during the pandemic are those with age-related macular degeneration (AMD). Many practices are performing some form of tele-ophthalmology services for their patients, and guidance is needed on how to maintain continuity of care amongst patients with AMD using tele-ophthalmology.
Methods
A literature search was conducted, ending 1 August 2020, to identify AMD outcomes and telecare management strategies that could be used during the COVID-19 pandemic
Results
237 total articles were retrieved, 56 of which were included for analysis. Four American Academy of Ophthalmology and Center for Disease Control web resources were also included.
Discussion
Risk-stratification models have been developed that let providers readily screen existing patients for their future risk of neovascular AMD (nAMD). When used with at-home monitoring devices to detect nAMD, providers may be able to determine who should be contacted via tele-ophthalmology for screening. Telemedicine triage can be used for new complaints of vision loss to determine who should be referred to a retinal specialist for management of suspected nAMD. To increase access and provider flexibility, smartphone fundus photography images sent to a centralized tele-ophthalmology service can aid in the detection of nAMD. Considerations should also be made for COVID-19 transmission, and tele-ophthalmology can be used to screen patients for the presence of COVID-19 prior to in-person office visits. Tele-ophthalmology has additional utility in connecting with nursing home, rural, and socioeconomically disadvantaged patients in the post-pandemic period.
KhachfeHHChahrourMSammouriJ, et al.
An epidemiological study on COVID-19: A rapidly spreading disease. Cureus2020;
12: e7313.
2.
McMichaelTMCurrieDWClarkS, et al. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. N Engl J Med Epub ahead of print 2020. DOI: 10.1056/nejmoa2005412.
3.
GargSKimLWhitakerM, et al.
Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep2020;
69: 458–464.
Al-ZamilWYassinS.Recent developments in age-related macular degeneration: A review. Clin Intervent Aging2017;
12: 1313–1330.
7.
JagerRDMielerWFMillerJW.Age-related macular degeneration. N Engl J Med2008;
358: 2606–2617.
8.
RuanQYangKWangW, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. Epub ahead of print 3 March 2020. DOI: 10.1007/s00134-020-05991-x.
9.
MuetherPSHoersterRHermannMM, et al.
Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol2013;
251: 453–458.
10.
TakahashiHOhkuboYSatoA, et al.
Relationship between visual prognosis and delay of intravitreal injection of ranibizumab when treating age-related macular degeneration. Retina2015;
35: 1331–1338.
11.
WintergerstMWMBouwsJLossJ, et al. [
Reasons for delayed and discontinued therapy in age-related macular degeneration]. Ophthalmologe2018;
115: 1035–1041.
12.
SimPYGajreeSDhillonB, et al.
Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: A retrospective cross-sectional study. BMJ Open2017;
7: e017771.
13.
VaranoMEterNWinyardS, et al.
Current barriers to treatment for wet age-related macular degeneration (wAMD): Findings from the wAMD patient and caregiver survey. Clin Ophthalmol2015;
9: 2243–2250.
14.
KisslerSMTedijantoCGoldsteinE, et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. Epub ahead of print 14 April 2020. DOI: 10.1126/science.abb5793.
15.
ParkeDWII. Ophthalmology after Coronavirus Disease 2019 (COVID-19): Transition back to patient care. JAMA Ophthalmol. Epub ahead of print 4 May 2020. DOI: 10.1001/jamaophthalmol.2020.2004.
16.
FlaxelCJAdelmanRABaileyST, et al.
Age-related macular degeneration preferred practice pattern®. Ophthalmology2020;
127: P1–P65.
17.
US Preventive Services Task Force (USPSTF),SiuALBibbins-DomingoK, et al.
Screening for impaired visual acuity in older adults: US Preventive Services Task Force Recommendation Statement. JAMA2016;
315: 908–914.
18.
CookHLPatelPJTufailA.Age-related macular degeneration: Diagnosis and management. Br Med Bull2008;
85: 127–149.
19.
FerrisFLDavisMDClemonsTE, et al.
A simplified severity scale for age-related macular degeneration: AREDS Report No. 18.Arch Ophthalmol2005;
123: 1570–1574.
20.
Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Macular Photocoagulation Study Group. Arch Ophthalmol1997;
115: 741–747.
21.
YanagiYMohlaALeeSY, et al.
Incidence of fellow eye involvement in patients with unilateral exudative age-related macular degeneration. JAMA Ophthalmol2018;
136: 905–911.
Schmidt-ErfurthUChongVLoewensteinA, et al.
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol2014;
98: 1144–1167.
24.
SinghNSrinivasanSMuralidharanV, et al.
Prevention of age-related macular degeneration. Asia Pac J Ophthalmol (Phila)2017;
6: 520–526.
25.
RasmussenABrandiSFuchsJ, et al.
Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration. Acta Ophthalmol2015;
93: 616–620.
26.
KeanePAde SalvoGSimDA, et al.
Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration. Clin Ophthalmol2015;
9: 353–366.
27.
MehtaHTufailADaienV, et al.
Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res2018;
65: 127–146.
28.
MathewRSivaprasadS.Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration. Eye2012;
26: 389–393.
29.
AREDS2-HOME Study Research Group, ChewEYClemonsTE, et al.
Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology2014;
121: 535–544.
30.
WangY-ZHeY-GMitzelG, et al.
Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. Invest Ophthalmol Vis Sci2013;
54: 5497–5505.
31.
TrevinoR.Recent progress in macular function self-assessment. Ophthalmic Physiol Opt2008;
28: 183–192.
32.
RathiSTsuiEMehtaN, et al.
The current state of teleophthalmology in the United States. Ophthalmology2017;
124: 1729–1734.
Oliver-FernandezABakalJSegalS, et al.
Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol2005;
40: 313–319.
35.
LimJHWickremasingheSSXieJ, et al.
Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol2012;
153: 678–86, 686.e1–2.
36.
HessellundALarsenDABekT.The predictive value of subjective symptoms and clinical signs for the presence of treatment-requiring exudative age-related macular degeneration. Acta Ophthalmol2012;
90: 471–475.
37.
LiBPowellA-MHooperPL, et al.
Prospective evaluation of teleophthalmology in screening and recurrence monitoring of neovascular age-related macular degeneration: A randomized clinical trial. JAMA Ophthalmol2015;
133: 276–282.
38.
GongJYuSGongY, et al.
The diagnostic accuracy of optical coherence tomography angiography for neovascular age-related macular degeneration: A comparison with fundus fluorescein angiography. J Ophthalmol2016;
2016: 7521478.
39.
MokwaNFRistauTKeanePA, et al.
Grading of age-related macular degeneration: Comparison between color fundus photography, fluorescein angiography, and spectral domain optical coherence tomography. J Ophthalmol2013;
2013: 385915.
40.
WildeCPatelMLakshmananA, et al.
The diagnostic accuracy of spectral-domain optical coherence tomography for neovascular age-related macular degeneration: A comparison with fundus fluorescein angiography. Eye2015;
29: 602–610.
41.
ZawinkaCErgunESturM.Prevalence of patients presenting with neovascular age-related macular degeneration in an urban population. Retina2005;
25: 324–331.
42.
ThorntonJ.Covid-19: A&E visits in England fall by 25% in week after lockdown.BMJ2020; m1401.
43.
KeanePASaddaSR.Retinal imaging in the twenty-first century: State of the art and future directions. Ophthalmology2014;
121: 2489–2500.
44.
SutoSHiraokaTOshikaT.Fluorescein fundus angiography with smartphone.Retina2014;
34: 203–205.
45.
LordRKShahVASan FilippoAN, et al.
Novel uses of smartphones in ophthalmology. Ophthalmology2010;
117: 1274–1274.e3.
46.
ToyBCMyungDJHeL, et al.
Smartphone-based dilated fundus photography and near visual acuity testing as inexpensive screening tools to detect referral warranted diabetic eye disease. Retina2016;
36: 1000–1008.
RajalakshmiRArulmalarSUshaM, et al.
Validation of smartphone based retinal photography for diabetic retinopathy screening. PLoS One2015;
10: e0138285.
49.
BifolckEFinkAPedersenD, et al.
Smartphone imaging for the ophthalmic examination in primary care. JAAPA2018;
31: 34–38.
50.
WilsonCHortonMCavalleranoJ, et al.
Addition of primary care-based retinal imaging technology to an existing eye care professional referral program increased the rate of surveillance and treatment of diabetic retinopathy. Diabetes Care2005;
28: 318–322.
51.
HuangJLiuXWuZ, et al.
Macular and retinal nerve fiber layer thickness measurements in normal eyes with the Stratus OCT, the Cirrus HD-OCT, and the Topcon 3D OCT-1000. J Glaucoma2011;
20: 118–125.
52.
GandhiMYokoeDSHavlirDV. Asymptomatic transmission, the Achilles’ heel of current strategies to control Covid-19. N Engl J Med. Epub ahead of print 24 April 2020. DOI: 10.1056/NEJMe2009758.
53.
ForresterJDNassarAKMaggioPM, et al.
Precautions for operating room team members during the COVID-19 pandemic. J Am Coll Surg2020;
230: 1098–1101.
54.
PatelZMFernandez-MirandaJHwangPH, et al.
Letter: precautions for endoscopic transnasal skull base surgery during the COVID-19 pandemic. Neurosurgery2020;
87: E66–E67.
55.
HuKPatelJPatelBC. Ophthalmic Manifestations Of Coronavirus (COVID-19). In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2020.
56.
AbràmoffMDLavinPTBirchM, et al.
Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ Digit Med2018;
1: 39.
57.
TingDSWCheungCY-LLimG, et al.
Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. JAMA2017;
318: 2211–2223.
58.
TingDSWPasqualeLRPengL, et al.
Artificial intelligence and deep learning in ophthalmology. Br J Ophthalmol2019;
103: 167–175.
59.
Schmidt-ErfurthUWaldsteinSMKlimschaS, et al.
Prediction of individual disease conversion in early AMD using artificial intelligence. Invest Ophthalmol Vis Sci2018;
59: 3199–3208.
60.
BhuiyanAWongTYTingDSW, et al.
Artificial intelligence to stratify severity of age-related macular degeneration (AMD) and predict risk of progression to late AMD. Transl Vis Sci Technol2020;
9: 25.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
